These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12711184)

  • 21. Evaluation of the Intelisite capsule to deliver theophylline and frusemide tablets to the small intestine and colon.
    Clear NJ; Milton A; Humphrey M; Henry BT; Wulff M; Nichols DJ; Anziano RJ; Wilding I
    Eur J Pharm Sci; 2001 Jul; 13(4):375-84. PubMed ID: 11408152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influenza: a new treatment, oseltamivir].
    Vervaeren J
    J Pharm Belg; 2002; 57(5):97-102. PubMed ID: 12476676
    [No Abstract]   [Full Text] [Related]  

  • 23. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
    Chen Y; Ke M; Xu J; Lin C
    AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probenecid with oseltamivir for human influenza A (H5N1) virus infection?
    Howton JC
    N Engl J Med; 2006 Feb; 354(8):879-80. PubMed ID: 16495407
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults.
    Ermer JC; Haffey MB; Doll WJ; Martin P; Sandefer EP; Dennis K; Corcoran M; Trespidi L; Page RC
    Drug Metab Dispos; 2012 Feb; 40(2):290-7. PubMed ID: 22039171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
    Mulla H; Peek GJ; Harvey C; Westrope C; Kidy Z; Ramaiah R
    Anaesth Intensive Care; 2013 Jan; 41(1):66-73. PubMed ID: 23362894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
    Morimoto K; Kishimura K; Nagami T; Kodama N; Ogama Y; Yokoyama M; Toda S; Chiyoda T; Shimada R; Inano A; Kano T; Tamai I; Ogihara T
    J Pharm Sci; 2011 Sep; 100(9):3854-61. PubMed ID: 21607954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
    Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M
    Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
    Eisenberg EJ; Bidgood A; Cundy KC
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1949-52. PubMed ID: 9303391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
    Deng R; Lee AP; Maia M; Lim JJ; Burgess T; Horn P; Derby MA; Newton E; Tavel JA; Hanley WD
    Clin Pharmacokinet; 2018 Mar; 57(3):367-377. PubMed ID: 28639229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional differences in quinine absorption from the undisturbed human colon assessed using a timed release delivery system.
    Hebden JM; Wilson CG; Spiller RC; Gilchrist PJ; Blackshaw E; Frier ME; Perkins AC
    Pharm Res; 1999 Jul; 16(7):1087-92. PubMed ID: 10450935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.
    Sweeny DJ; Lynch G; Bidgood AM; Lew W; Wang KY; Cundy KC
    Drug Metab Dispos; 2000 Jul; 28(7):737-41. PubMed ID: 10859145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.
    Lindegardh N; Davies GR; Tran TH; Farrar J; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3197-9. PubMed ID: 16940130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
    Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M
    J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colon-specific delivery of dexamethasone from a glucoside prodrug in the guinea pig.
    Tozer TN; Rigod J; McLeod AD; Gungon R; Hoag MK; Friend DR
    Pharm Res; 1991 Apr; 8(4):445-54. PubMed ID: 1871038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
    Connor A; Evans P; Doto J; Ellis C; Martin DE
    J Clin Pharmacol; 2009 May; 49(5):606-12. PubMed ID: 19304891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Zanamivir, oseltamivir].
    Kashiwagi S
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():445-7. PubMed ID: 15658359
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.